ATC Group: C07AB09 Esmolol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C07AB09 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C07 Beta blocking agents
3 C07A Beta blocking agents
4 C07AB Beta blocking agents, selective
5 C07AB09 Esmolol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 2.5 g

Active ingredients in C07AB09

Active Ingredient Description
Esmolol

Esmolol is a beta-selective (cardioselective) receptor blocking agent. At therapeutic doses esmolol has no significant intrinsic sympathicomimetic activity (ISA) or membrane stabilising activity.

Related product monographs

Title Information Source Document Type  
ESMOLOL HYDROCHLORIDE Powder for concentrate solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Malta (MT)

Poland (PL)

Romania (RO)

South Africa (ZA)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.